$471 Million Social Impact Oncology Fund Launched
by
$471 Million Social Impact Oncology Fund Launched
by MPM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
MPM announces the launch of a first-in-kind social impact oncology fund, raised in partnership with UBS. The UBS Oncology Impact Fund (the “OIF”) held the final closing this month on $471 million in committed capital. The OIF is an evergreen, crossover fund dedicated to investing in cancer therapeutics. Twenty percent of the committed capital will be dedicated to public equity investments, and the balance to private companies. In general, the OIF will co-invest with MPM’s BV2014 venture fund in private oncology company investments. To date, the OIF and BV2014 have co-invested in four oncology companies.
Beyond financial returns, the OIF will also seek to make a positive social impact. MPM has dedicated a portion of its own profits from the OIF to providing access to cancer care in the developing world where cancer kills more people than AIDS, malaria and tuberculosis combined. An equal portion of its profits will go to cancer research. MPM and the American Association for Cancer Research will collaborate to identify promising academic research that is likely to have a transformative effect on future clinical practice.
“We were honored to be selected as UBS’ partner in this path-breaking endeavor. We are proud of our depth of experience and track record in shepherding breakthrough treatments to commercial success,” stated MPM Managing Director and co-founder Ansbert Gadicke, M.D. “As a firm we strive to foster a culture where we constantly ask ‘What can we do better?’ The OIF demonstrates our commitment to not just investing in innovation, but innovation in investment.”
MPM brings to the OIF initiative a team of Managing Directors with deep oncology and investing experience, many of whom have already played important roles developing recent cancer therapies. These include the foundational sciences behind the leukemia drug Gleevec® and the cervical cancer vaccine Gardasil®. Additional cancer drugs where MPM Managing Directors played an important role in development include Afinitor®, Tasigna®, Jakavi®, Nexavar®, Kyprolis® and Blincyto®. With the OIF, MPM will continue its practice of deploying these senior-level executives with relevant operating experience into portfolio companies. Two of MPM’s Managing Directors, Patrick Baeuerle, Ph.D. and Mitchell Finer, Ph.D. are already at the helm of companies that are joint MPM/OIF investments. The other team members are Christiana Bardon, M.D., founder of Burrage Capital, who will manage OIF’s public equities portfolio; Pablo Cagnoni, M.D., currently also CEO of MPM portfolio company Tizona Therapeutics; Bard Geesaman, M.D., Ph.D., who has worked with MPM and its associated portfolio companies since 2002; Dan Hicklin, Ph.D., currently also CEO of MPM portfolio company Potenza Therapeutics; Briggs Morrison, M.D., currently also CEO of MPM portfolio company Syndax Pharmaceuticals and Greg Sieczkiewicz, J.D., Ph.D., who serves as Chief IP Counsel for a number of joint MPM/OIF portfolio companies.
The OIF will also benefit from the guidance of an experienced Advisory Board, co-chaired by Robert Horvitz, M.D., winner of the Nobel Prize in Medicine for his work on cell apoptosis and George Daley, M.D., whose research on the cancer biology of leukemia led to the development of the first precision cancer drug, Gleevec®. Drs. Horvitz and Daley are joined on the Advisory Board by Thomas Ebeling, the former CEO of the global Novartis pharmaceutical business, and David Ryan, M.D., a skilled clinician who leads a renowned specialized oncology group at Massachusetts General Hospital.
About MPM -- MPM Capital (www.mpmcapital.com) is an early-stage life sciences venture investing firm with a track record of success in building world-class companies around transformational treatments and cures. With its deep experience, dedicated team of operating executives and distinguished MSAB, MPM Capital is powering medical breakthroughs that change lives.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...
Continue Reading
A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...
Continue Reading
Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...
Continue Reading
Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...
Continue Reading
Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...
Continue Reading
A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...
Continue Reading
Spreadsheets breed little kingdoms, and SAP is often left outside the gate. That is the operational mess Martin Rowan, managing partner at Reveal USA, Inc. in Naperville, is taking aim at in a Nov. 19, 2026 HelloNation feature. His central point is not terribly glamorous, but it is dead right: a company gets less stable when it uses SAP to explain yesterday's results...
Continue Reading
A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...
Continue Reading
Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...
Continue Reading
A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...
Continue Reading
Top 5 Most Recently Viewed Articles
Autohome Inc.'s Upcoming Financial Results Announcement Autohome Inc. (NYSE: ATHM) is on the verge of announcing its financial results for the second quarter and six months period ending June 30, 2025. As a leading platform for automobile consumers, Autohome continues to grow and adapt in an evolving market. Key Details on the Earnings Announcement The earnings report...
Continue Reading
NEXGEL Expands Scientific Expertise with New Appointment NEXGEL, Inc. (NASDAQ: NXGL), renowned for its innovative medical and over-the-counter (OTC) products, has recently announced an exciting development. The company is thrilled to welcome Kip Crecca to its Scientific Advisory Board. This strategic addition showcases NEXGEL's dedication to enhancing its healthcare...
Continue Reading
Reimagining Urban Spaces: The Lewter District Development In an exciting development for urban living, RNGD and Emergent Properties are pioneering a remarkable mixed-use community known as the Lewter District. This project is set on a 1.5-acre plot, featuring 14 townhomes, a Class A office building, and an inviting farm-to-table restaurant, bar, and bakery. It's an...
Continue Reading
Picking Up Momentum in Dallas-Fort Worth Real Estate 37th Parallel Properties isn't messing around in the Dallas-Fort Worth market. They've snapped up Woodbridge Villas, a prime multifamily asset with 222 units tucked away in Sachse, Texas—a place with more charm than lawn gnomes in spring. This acquisition helps them expand their already hefty footprint in the South...
Continue Reading
Microchip Technology's Updated Revenue Guidance for December Quarter Recently, Microchip Technology Incorporated, a prominent provider of smart embedded control solutions, has updated its revenue outlook for the upcoming quarter. The latest forecasts indicate a decline, with expectations set close to the lower end of their original guidance at $1.025 billion. This...
Continue Reading